icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Barcelona, Spain
13-17 April 2016
Back grey_arrow_rt.gif
 
 
 
Ledipasvir/Sofosbuvir With Ribavirin for 12 Weeks Is Effective and Safe in Treatment-Na´ve Genotype 3 HCV-Infected Patients in Canada
 
 
  Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
 
Jordan J. Feld,1 Alnoor Ramji,2 Stephen Shafran,3 Bernard Willlems,4 Paul Marotta,5 Emmanuelle Huchet,6 Marie-Louise Vachon,7 Evguenia S. Svarovskaia,8 K.C. Huang,8 Robert H. Hyland,8 Chohee Yun,8
Diana M. Brainard,8 John G. McHutchison,8 Edward Tam,9 Robert Bailey,10 Curtis Cooper,11 Eric Yoshida,12 Susan Greenbloom,13 Magdy Elkhashab,14 Sergio Borgia,15 Mark Swain16 1Toronto Western Hospital Francis Family Liver Clinic, Toronto, Ontario, Canada; 2GI Research Institute, Vancouver, British Columbia, Canada; 3University of Alberta, Edmonton, Canada; 4Centre Hospitalier de l'Universite de Montreal, Hopital Saint-Luc, Quebec, Canada; 5London Health Sciences Centre, London, Ontario; 6Clinique Medicale l'Actuel, Montreal; 7Centre Hospitalier Universitaire de Quebec, Ville de Quebec; 8Gilead Sciences, Inc., Foster City, California, USA; 9LAIR Centre, Vancouver; 10The Centre of Excellence for Gastrointestinal Inflammation and Immunity Research, Edmonton; 11The Ottawa Hospital, Ottawa, Ontario; 12Vancouver General Hospital, Vancouver; 13Toronto Digestive Disease Associates Inc., Vaughan, Ontario; 14Toronto Liver Centre, Toronto; 15William Osler Health System, Brampton, Ontario; 16University of Calgary, Alberta

EASL1

EASL2

EASL3

EASL4

EASL5